驱动力(838275) - 2024 Q4 - 年度业绩预告

Financial Performance - The company forecasts a net profit attributable to shareholders between 10 million to 15 million RMB, representing an increase of 69% to 154% compared to the previous year[4] - The company has seen an increase in net profit due to a rise in interest income by approximately 4 million RMB[5] - The recovery of accounts receivable has positively impacted net profit, with a change of approximately 4.7 million RMB in credit impairment losses[5] Revenue and Profit Margins - The sales revenue of higher-margin products in the hematopoietic series has increased, leading to an overall improvement in gross profit margin[4] Forecast and Reporting - The performance forecast is based on preliminary calculations and may differ from the final data in the annual report[6]